COST EFFECTIVENESS OF APIXABAN, DABIGATRAN RIVAROXABAN AND WARFARIN FOR ATRIAL FIBRILLATION IN GUATEMALA
Author(s)
Garita M1, Peralta M1, Gordillo DI2
1Pfizer Central America and Caribbean, Escazu, San Jose, Costa Rica, 2Hospital Universitario Esperanza, Guatemala, Guatemala
OBJECTIVES: Atrial Fibrillation (AF) affects 1–2% of the population, and this figure is likely to increase in the next 50 years. AF is associated with increased rates of death, stroke and other thromboembolic events, heart failure and hospitalizations, degraded quality of life and reduced exercise capacity. It is suggested that patients with AF should be stratified for the risk of stroke and bleedings and that most should receive antithrombotic therapy. The aim of this study was to assess the cost-effectiveness (CE) of Apixaban against other anticoagulation therapies for prevention on non-valvular atrial fibrillation (NVAF), from the private healthcare perspective. METHODS: RESULTS:
Conference/Value in Health Info
2014-05, ISPOR 2014, Palais des Congres de Montreal
Value in Health, Vol. 17, No. 3 (May 2014)
Code
PCV77
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Cardiovascular Disorders